Skip to main content

Table 3 Baseline characteristics of the participants

From: Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patients—rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial

Total number 976
Age (years) 63.5 ± 10.0
Sex, men (%) 60.5
Underlying renal disease, diabetic nephropathy (%) 42.5
Years on hemodialysis, 5 years or longer (%) 52.2
Prior cardiovascular disease, present (%) 25.1
Serum calcium (mg/dL) 8.82 ± 0.60
Serum phosphate (mg/dL) 4.56 ± 0.91
Serum intact parathyroid hormone (pg/mL) 86.6 (46.8–130.0)
Use of calcium carbonate (%) 82.9
Use of sevelamer hydrochloride (%) 32.0
Use of lanthanum carbonate (%) 12.4
Use of cinacalcet hydrochloride (%) 5.9
  1. The table gives number, percentage, mean ± standard deviation, or median (25th–75th percentile)